Update shared on 08 Nov 2025
Analysts have maintained their price target for USANA Health Sciences steady at $39.00. They cited consistent growth and profitability estimates as justification for holding the previous valuation.
What's in the News
- USANA Health Sciences, Inc. was dropped as a constituent from the S&P 600, S&P Composite 1500, and S&P 1000 indices, as well as from the S&P 600 Consumer Staples sector (Key Developments).
- The company revised its fiscal 2025 guidance downward, forecasting net sales of $920 million and diluted EPS of $0.78. This compares to prior guidance of up to $1.0 billion in net sales and EPS of up to $2.20 (Key Developments).
- USANA is seeking acquisitions and investment opportunities as part of its future diversification strategy, according to its President and CEO during the third quarter earnings call (Key Developments).
- USANA’s top-rated Vitamin D supplement earned the ConsumerLab.com Seal of Approval, reflecting its commitment to third-party validation and product excellence (Key Developments).
- The company launched new and upgraded products across its nutritionals and Celavive skincare lines. It also formed a Health Professional Advisory Council to support product innovation (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $39.00 per share.
- The discount rate has declined slightly to approximately 7.44% from 7.52%.
- Revenue growth projection stays steady at 21.34%.
- Net profit margin expectation is unchanged at 6.08%.
- The future P/E ratio has decreased marginally to 13.85x from 13.89x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.